Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2008 (2008), Article ID 897508, 8 pages
http://dx.doi.org/10.1155/2008/897508
Research Article

Decreased ADP-Ribosyl Cyclase Activity in Peripheral Blood Mononuclear Cells from Diabetic Patients with Nephropathy

1Division of Endocrinology and Diabetology, Kanazawa University Graduate School of Medicine, 13-1 Takaramachi, Kanazawa 920 8640, Japan
2Division of Cardiovascular Medicine, Department of Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takaramachi, Kanazawa 920 8640, Japan
3Department of Biophysical Genetics, Kanazawa University Graduate School of Medicine, 13-1 Takaramachi, Kanazawa 920 8640, Japan

Received 30 September 2008; Accepted 12 December 2008

Academic Editor: Andreas Pfützner

Copyright © 2008 Michio Ohtsuji et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at PubMed
  2. W. F. Keane, K. Kurokawa, P. A. Lyle et al., “Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists: lessons from recent trials,” Clinical and Experimental Nephrology, vol. 6, no. 4, pp. 175–181, 2002. View at Publisher · View at Google Scholar
  3. T. Usami, K. Koyama, O. Takeuchi, K. Morozumi, and G. Kimura, “Regional variations in the incidence of end-stage renal failure in Japan,” The Journal of the American Medical Association, vol. 284, no. 20, pp. 2622–2624, 2000. View at Publisher · View at Google Scholar
  4. K. Kurokawa, J. C. N. Chan, M. E. Cooper, W. F. Keane, S. Shahinfar, and Z. Zhang, “Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study,” Clinical and Experimental Nephrology, vol. 10, no. 3, pp. 193–200, 2006. View at Publisher · View at Google Scholar · View at PubMed
  5. M.-L. Gross, R. Dikow, and E. Ritz, “Diabetic nephropathy: recent insights into the pathophysiology and the progression of diabetic nephropathy,” Kidney International, vol. 67, pp. S50–S53, 2005. View at Publisher · View at Google Scholar · View at PubMed
  6. H. Abrahamian, G. Endler, M. Exner et al., “Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines,” Experimental and Clinical Endocrinology & Diabetes, vol. 115, no. 1, pp. 38–41, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. B. A. Young, R. J. Johnson, C. E. Alpers et al., “Cellular events in the evolution of experimental diabetic nephropathy,” Kidney International, vol. 47, no. 3, pp. 935–944, 1995. View at Publisher · View at Google Scholar
  8. C.-G. Ihm, J.-K. Park, S.-P. Hong et al., “A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells,” Nephron, vol. 79, no. 1, pp. 33–37, 1998. View at Publisher · View at Google Scholar
  9. P. Cortes, X. Zhao, B. L. Riser, and R. G. Narins, “Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy,” Kidney International, vol. 51, no. 1, pp. 57–68, 1997. View at Publisher · View at Google Scholar
  10. J. F. Navarro-González and C. Mora-Fernández, “The role of inflammatory cytokines in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 433–442, 2008. View at Publisher · View at Google Scholar · View at PubMed
  11. S. Okada, K. Shikata, M. Matsuda et al., “Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes,” Diabetes, vol. 52, no. 10, pp. 2586–2593, 2003. View at Publisher · View at Google Scholar
  12. H. Sugimoto, K. Shikata, K. Hirata et al., “Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation,” Diabetes, vol. 46, no. 12, pp. 2075–2081, 1997. View at Publisher · View at Google Scholar
  13. H. C. Lee, “Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers,” Annual Review of Pharmacology and Toxicology, vol. 41, pp. 317–345, 2001. View at Publisher · View at Google Scholar · View at PubMed
  14. M. Howard, J. C. Grimaldi, J. F. Bazan et al., “Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38,” Science, vol. 262, no. 5136, pp. 1056–1059, 1993. View at Publisher · View at Google Scholar
  15. S. Takasawa, A. Tohgo, N. Noguchi et al., “Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP,” The Journal of Biological Chemistry, vol. 268, no. 35, pp. 26052–26054, 1993. View at Google Scholar
  16. E. Zocchi, L. Franco, L. Guida et al., “A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes,” Biochemical and Biophysical Research Communications, vol. 196, no. 3, pp. 1459–1465, 1993. View at Publisher · View at Google Scholar
  17. F. Malavasi, S. Deaglio, A. Funaro et al., “Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology,” Physiological Reviews, vol. 88, no. 3, pp. 841–886, 2008. View at Publisher · View at Google Scholar · View at PubMed
  18. S.-Y. Kim, R. Gul, S.-Y. Rah et al., “Molecular mechanism of ADP-ribosyl cyclase activation in angiotensin II signaling in murine mesangial cells,” American Journal of Physiology, vol. 294, no. 4, pp. F982–F989, 2008. View at Publisher · View at Google Scholar · View at PubMed
  19. M. J. Berridge, P. Lipp, and M. D. Bootman, “The versatility and universality of calcium signalling,” Nature Reviews Molecular Cell Biology, vol. 1, no. 1, pp. 11–21, 2000. View at Publisher · View at Google Scholar · View at PubMed
  20. E. Carafoli, L. Santella, D. Branca, and M. Brini, “Generation, control, and processing of cellular calcium signals,” Critical Reviews in Biochemistry and Molecular Biology, vol. 36, no. 2, pp. 107–260, 2001. View at Publisher · View at Google Scholar · View at PubMed
  21. H. Higashida, M. Hashii, S. Yokoyama, N. Hoshi, K. Asai, and T. Kato, “Cyclic ADP-ribose as a potential second messenger for neuronal Ca2+ signaling,” Journal of Neurochemistry, vol. 76, no. 2, pp. 321–331, 2001. View at Publisher · View at Google Scholar
  22. A. H. Guse, “Cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP): novel regulators of Ca2+-signaling and cell function,” Current Molecular Medicine, vol. 2, no. 3, pp. 273–282, 2002. View at Publisher · View at Google Scholar
  23. H. C. Lee, Cyclic ADP-Ribose and NAADP: Structure, Metabolism and Functions, Springer, Dordrecht, The Netherlands, 2001.
  24. F.-X. Boittin, M. Dipps, N. P. Kinnear, A. Galione, and A. M. Evans, “Vasodilation by the calcium-mobilizing messenger cyclic ADP-ribose,” The Journal of Biological Chemistry, vol. 278, no. 11, pp. 9602–9608, 2003. View at Publisher · View at Google Scholar · View at PubMed
  25. D. A. Deshpande, T. F. Walseth, R. A. Panettieri, and M. S. Kannan, “CD38/cyclic ADP-ribose-mediated Ca2+ signaling contributes to airway smooth muscle hyper-responsiveness,” The FASEB Journal, vol. 17, no. 3, pp. 452–454, 2003. View at Publisher · View at Google Scholar · View at PubMed
  26. T.-S. Nam, H. C. Sung, S.-Y. Rah et al., “Discovery of a small-molecule inhibitor for kidney ADP-ribosyl cyclase: implication for intracellular calcium signal mediated by cyclic ADP-ribose,” Experimental and Molecular Medicine, vol. 38, no. 6, pp. 718–726, 2006. View at Google Scholar
  27. B. J. Kim, K. H. Park, C. Y. Yim et al., “Generation of nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose by glucagon-like peptide-1 evokes Ca2+ signal that is essential for insulin secretion in mouse pancreatic islets,” Diabetes, vol. 57, no. 4, pp. 868–878, 2008. View at Publisher · View at Google Scholar · View at PubMed
  28. E. G. Teggatz, G. Zhang, A. Y. Zhang et al., “Role of cyclic ADP-ribose in Ca2+-induced Ca2+ release and vasoconstriction in small renal arteries,” Microvascular Research, vol. 70, no. 1-2, pp. 65–75, 2005. View at Publisher · View at Google Scholar · View at PubMed
  29. S. Bruzzone, A. De Flora, C. Usai, R. Graeff, and H. C. Lee, “Cyclic ADP-ribose is a second messenger in the lipopolysaccharide-stimulated proliferation of human peripheral blood mononuclear cells,” The Biochemical Journal, vol. 375, part 2, pp. 395–403, 2003. View at Publisher · View at Google Scholar · View at PubMed
  30. J. R. Gavin, K. G. M. M. Alberti, M. B. Davidson et al., “Report of the expert committee on the diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 20, no. 7, pp. 1183–1197, 1997. View at Google Scholar
  31. K. G. M. M. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus and its complications—part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation,” Diabetic Medicine, vol. 15, no. 7, pp. 539–553, 1998. View at Publisher · View at Google Scholar
  32. M. Buysschaert, A.-S. Dramais, P. E. Wallemacq, and M. P. Hermans, “Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance,” Diabetes Care, vol. 23, no. 12, pp. 1816–1822, 2000. View at Publisher · View at Google Scholar
  33. A. Bøyum, “Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g,” Scandinavian Journal of Clinical and Laboratory Investigation. Supplement, vol. 97, pp. 77–89, 1968. View at Google Scholar
  34. A. Bøyum, “Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents,” Scandinavian Journal of Clinical and Laboratory Investigation. Supplement, vol. 97, pp. 31–50, 1968. View at Google Scholar
  35. A. Bøyum, “Isolation of lymphocytes, granulocytes and macrophages,” Scandinavian Journal of Immunology. Supplement, vol. 5, pp. 9–15, 1976. View at Google Scholar
  36. H. Higashida, A. Egorova, C. Higashida et al., “Sympathetic potentiation of cyclic ADP-ribose formation in rat cardiac myocytes,” The Journal of Biological Chemistry, vol. 274, no. 47, pp. 33348–33354, 1999. View at Publisher · View at Google Scholar
  37. H. Higashida, J.-S. Zhang, M. Hashii, M. Shintaku, C. Higashida, and Y. Takeda, “Angiotensin II stimulates cyclic ADP-ribose formation in neonatal rat cardiac myocytes,” The Biochemical Journal, vol. 352, part 1, pp. 197–202, 2000. View at Publisher · View at Google Scholar
  38. R. M. Graeff, T. F. Walseth, K. Fryxell, W. D. Branton, and H. C. Lee, “Enzymatic synthesis and characterizations of cyclic GDP-ribose. A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity,” The Journal of Biological Chemistry, vol. 269, no. 48, pp. 30260–30267, 1994. View at Google Scholar
  39. R. M. Graeff, L. Franco, A. De Flora, and H. C. Lee, “Cyclic GMP-dependent and -independent effects on the synthesis of the calcium messengers cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate,” The Journal of Biological Chemistry, vol. 273, no. 1, pp. 118–125, 1998. View at Publisher · View at Google Scholar
  40. C. M. Ausiello, A. La Sala, C. Ramoni, F. Urbani, A. Funaro, and F. Malavasi, “Secretion of IFN-γ, IL-6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after activation of human purified T lymphocytes upon CD38 ligation,” Cellular Immunology, vol. 173, no. 2, pp. 192–197, 1996. View at Publisher · View at Google Scholar · View at PubMed
  41. M.-A. Kumagai, E. Coustan-Smith, D. J. Murray et al., “Ligation of CD38 suppresses human B lymphopoiesis,” The Journal of Experimental Medicine, vol. 181, no. 3, pp. 1101–1110, 1995. View at Publisher · View at Google Scholar
  42. A. Kitanaka, C. Ito, H. Nishigaki, and D. Campana, “CD38-mediated growth suppression of B-cell progenitors requires activation of phosphatidylinositol 3-kinase and involves its association with the protein product of the c-cbl proto-oncogene,” Blood, vol. 88, no. 2, pp. 590–598, 1996. View at Google Scholar
  43. E. Todisco, T. Suzuki, K. Srivannaboon et al., “CD38 ligation inhibits normal and leukemic myelopoiesis,” Blood, vol. 95, no. 2, pp. 535–542, 2000. View at Google Scholar
  44. M.-T. Zilber, S. Gregory, R. Mallone et al., “CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 6, pp. 2840–2845, 2000. View at Publisher · View at Google Scholar · View at PubMed
  45. T. Musso, S. Deaglio, L. Franco et al., “CD38 expression and functional activities are up-regulated by IFN-γ on human monocytes and monocytic cell lines,” Journal of Leukocyte Biology, vol. 69, no. 4, pp. 605–612, 2001. View at Google Scholar
  46. M. Pfister, A. Ogilvie, C. P. da Silva, A. Grahnert, A. H. Guse, and S. Hauschildt, “NAD degradation and regulation of CD38 expression by human monocytes/macrophages,” European Journal of Biochemistry, vol. 268, no. 21, pp. 5601–5608, 2001. View at Publisher · View at Google Scholar
  47. M. Alessio, S. Roggero, A. Funaro et al., “CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells,” The Journal of Immunology, vol. 145, no. 3, pp. 878–884, 1990. View at Google Scholar
  48. K. M. McNagny, P.-A. Cazenave, and M. D. Cooper, “BP-3 alloantigen. A cell surface glycoprotein that marks early B lineage cells and mature myeloid lineage cells in mice,” The Journal of Immunology, vol. 141, no. 8, pp. 2551–2556, 1988. View at Google Scholar
  49. A. M. Di Giulio, E. Lesma, E. Germani, and A. Gorio, “Inhibition of high glucose-induced protein mono-ADP-ribosylation restores neuritogenesis and sodium-pump activity in SY5Y neuroblastoma cells,” Journal of Neuroscience Research, vol. 57, no. 5, pp. 663–669, 1999. View at Publisher · View at Google Scholar
  50. C. Pupilli, S. Giannini, P. Marchetti et al., “Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets,” Diabetes, vol. 48, no. 12, pp. 2309–2315, 1999. View at Publisher · View at Google Scholar
  51. R. Mallone, E. Ortolan, G. Baj et al., “Autoantibody response to CD38 in Caucasian patients with type 1 and type 2 diabetes: immunological and genetic characterization,” Diabetes, vol. 50, no. 4, pp. 752–762, 2001. View at Publisher · View at Google Scholar
  52. A. Antonelli and E. Ferrannini, “CD38 autoimmunity: recent advances and relevance to human diabetes,” Journal of Endocrinological Investigation, vol. 27, no. 7, pp. 695–707, 2004. View at Google Scholar
  53. A. Antonelli, G. Baj, P. Marchetti et al., “Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets,” Diabetes, vol. 50, no. 5, pp. 985–991, 2001. View at Publisher · View at Google Scholar
  54. A. Antonelli, T. Tuomi, M. Nannipieri et al., “Autoimmunity to CD38 and GAD in type I and type II diabetes: CD38 and HLA genotypes and clinical phenotypes,” Diabetologia, vol. 45, no. 9, pp. 1298–1306, 2002. View at Publisher · View at Google Scholar · View at PubMed
  55. R. Mallone, E. Ortolan, S. Pinach et al., “Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparison with other islet autoantibodies,” Diabetologia, vol. 45, no. 12, pp. 1667–1677, 2002. View at Publisher · View at Google Scholar · View at PubMed
  56. S. Takasawa, K. Nata, H. Yonekura, and H. Okamoto, “Cyclic ADP-ribose in insulin secretion from pancreatic β cells,” Science, vol. 259, no. 5093, pp. 370–373, 1993. View at Publisher · View at Google Scholar
  57. H. Okamoto, S. Takasawa, and K. Nata, “The CD38-cyclic ADP-ribose signalling system in insulin secretion: molecular basis and clinical implications,” Diabetologia, vol. 40, no. 12, pp. 1485–1491, 1997. View at Publisher · View at Google Scholar
  58. N.-H. An, M.-K. Han, C. Um et al., “Significance of ecto-cyclase activity of CD38 in insulin secretion of mouse pancreatic islet cells,” Biochemical and Biophysical Research Communications, vol. 282, no. 3, pp. 781–786, 2001. View at Publisher · View at Google Scholar · View at PubMed
  59. H. Okamoto and S. Takasawa, “Recent advances in physiological and pathological significance of NAD+ metabolites: roles of poly(ADP-ribose) and cyclic ADP-ribose in insulin secretion and diabetogenesis,” Nutrition Research Reviews, vol. 16, no. 2, pp. 253–266, 2003. View at Publisher · View at Google Scholar · View at PubMed
  60. H. Okamoto and S. Takasawa, “Recent advances in the Okamoto model: the CD38-cyclic ADP-ribose signal system and the regenerating gene protein (Reg)-Reg receptor system in β-cells,” Diabetes, vol. 51, pp. S462–S473, 2002. View at Publisher · View at Google Scholar
  61. H. Okamoto, S. Takasawa, K. Nata, I. Kato, A. Tohgo, and N. Noguchi, “Physiological and pathological significance of the CD38-cyclic ADP-ribose signaling system,” in Human CD38 and Related Molecules, K. Mehta and F. Malavasi, Eds., vol. 75 of Chemical Immunology, pp. 121–145, S. Karger, Basel, Switzerland, 2000. View at Google Scholar
  62. Z. Liu, W. G. Cumberland, L. E. Hultin, H. E. Prince, R. Detels, and J. V. Giorgi, “Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS Cohort study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 16, no. 2, pp. 83–92, 1997. View at Google Scholar
  63. J. V. Giorgi, H.-N. Ho, K. Hirji et al., “CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels,” The Journal of Infectious Diseases, vol. 170, no. 4, pp. 775–781, 1994. View at Google Scholar
  64. S. Deaglio, S. Aydin, T. Vaisitti, L. Bergui, and F. Malavasi, “CD38 at the junction between prognostic marker and therapeutic target,” Trends in Molecular Medicine, vol. 14, no. 5, pp. 210–218, 2008. View at Publisher · View at Google Scholar · View at PubMed